ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure

A 14-year-long partnership with Amgen is coming to an end this week, but Cytokinetics is pressing on to file the heart drug the two companies collaborated on to the FDA—in more of a supporting role than originally planned.